Arix Bioscience PLC has released its unaudited estimated Net Asset Value (NAV) for August 2023. The NAV breakdown for the date ended 31 August 2023 is as follows: Total NAV of £66.9 million, with £66.2 million in the listed portfolio, £100 million in the unlisted portfolio, £2.8 million in cash, and £235.9 million in other interests. The NAV per share is £1.82. Arix Bioscience is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies. They collaborate with entrepreneurs and provide capital, expertise, and global networks to accelerate the development of new treatments for patients. Arix Bioscience is listed on the London Stock Exchange.